Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 6,974 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal and Urinary Disorders Clear all
Completed Phase 4 Interventional

Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium

NCT00073710
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Zemplar, 42 Ca carbonate absorption via single tracer method, Calcijex
Drug · Procedure
Lead sponsor
Abbott
Industry
Eligibility
20 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 2, 2006 · Synced Oct 6, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00082823
View directory record Official record
Conditions
Cancer
Interventions
ziv-aflibercept
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 6, 2026, 4:03 PM EDT
Recruiting Phase 1 Interventional

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

NCT07195682
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
BMS-986506, Pumitamig, Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 6, 2026, 4:03 PM EDT
Completed Not applicable Interventional

Absorbable Suture vs Permanent Suture in Sacrospinous Ligament Suspension

NCT05688059
View directory record Official record
Conditions
Pelvic Organ Prolapse, Uterovaginal Prolapse, Vaginal Vault Prolapse, Cystocele
Interventions
Absorbable Suture and Permanent Suture
Other
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 6, 2026, 4:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Value of Urodynamic Evaluation

NCT00803959
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Office evaluation, UDS
Other
Lead sponsor
Carelon Research
Other
Eligibility
21 Years and older · Female only
Enrollment
630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Maywood, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Oct 6, 2026, 4:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function

NCT03482024
View directory record Official record
Conditions
Renal Insufficiency, End Stage Renal Disease
Interventions
Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Tustin, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 6, 2026, 4:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Can Investigators Reduce Urinary Catheter Use and Lower Urinary Tract Infection Among Women Undergoing Benign Gynecologic Surgery?

NCT03127280
View directory record Official record
Conditions
Urinary Tract Infections, Urinary Retention, Satisfaction
Interventions
Fast Track foley removal
Other
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Oct 6, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

NCT02127710
View directory record Official record
Conditions
Papillary Renal Cell Cancer
Interventions
AZD6094
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 6, 2026, 4:03 PM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer

NCT02143804
View directory record Official record
Conditions
Bladder Cancer, High Grade, Non Muscle Invasive
Interventions
oncolytic adenovirus expressing GMCSF
Biological
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 6, 2026, 4:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment

NCT00768404
View directory record Official record
Conditions
Renal Impairment
Interventions
Topirmate and Phentermine
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Anaheim, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Oct 6, 2026, 4:03 PM EDT
Terminated Phase 1 Interventional

HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma

NCT02947152
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Renal Cell Carcinoma
Interventions
HKT288
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 6, 2026, 4:03 PM EDT
Completed No phase listed Observational

Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-treated Children

NCT00308906
View directory record Official record
Conditions
Infection, Renal Dysfunction
Interventions
aminoglycoside
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Up to 18 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Louisville, Kentucky • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Oct 6, 2026, 4:03 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

NCT05581004
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Colorectal Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
Interventions
Enzelkitug, Atezolizumab, Pembrolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
10
States / cities
San Francisco, California • Aurora, Colorado • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 6, 2026, 4:03 PM EDT
Completed No phase listed Observational

Blood Volume Analysis and Renal Outcomes in Hemodialysis

NCT02717533
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis, Actual Impaired Fluid Volume, Kidney Failure
Interventions
dry weight adjustment
Other
Lead sponsor
VA New York Harbor Healthcare System
Federal
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 6, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant

NCT00357084
View directory record Official record
Conditions
Cancer
Interventions
methotrexate, methylprednisolone, prednisone
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 6, 2026, 4:03 PM EDT
Completed Phase 1 Interventional Results available

Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze

NCT00634504
View directory record Official record
Conditions
Osteosarcoma, Leukemia, Lymphoma
Interventions
glucarpidase, high-dose methotrexate, leucovorin, high-dose methotrexate, leucovorin
Drug
Lead sponsor
BTG International Inc.
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 6, 2026, 4:03 PM EDT
Recruiting Not applicable Interventional

Aquarius Pilot Study to Evaluate the New Axonics Trial System

NCT07335484
View directory record Official record
Conditions
Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI), Overactive Bladder (OAB)
Interventions
Axonics External Trial System (ETS)
Device
Lead sponsor
Axonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
West Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 6, 2026, 4:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine

NCT02606084
View directory record Official record
Conditions
Renal Impairment, Healthy
Interventions
Esketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
2
States / cities
Miami, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 6, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction

NCT01220726
View directory record Official record
Conditions
Overactive Bladder
Interventions
Botox, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years to 90 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 6, 2026, 4:03 PM EDT
Not listed Phase 1 Interventional

Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features

NCT00314925
View directory record Official record
Conditions
Carcinoid, Neuroendocrine
Interventions
Seneca Valley Virus (biological agent)
Drug
Lead sponsor
Neotropix
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Ocoee, Florida • Indianapolis, Indiana • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2010 · Synced Oct 6, 2026, 4:03 PM EDT
Enrolling by invitation No phase listed Observational

Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0

NCT06823115
View directory record Official record
Conditions
Acute Kidney Injury, Fluid Overload, Prematurity Complications, Risk Factors, Epidemiology, Chronic Kidney Disease(CKD), Hypertension
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
0 Minutes to 2 Weeks
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
50
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 6, 2026, 4:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects

NCT00911235
View directory record Official record
Conditions
Overactive Bladder With Symptoms of Frequency, Urgency, and Urge Urinary Incontinence
Interventions
Fesoterodine, fesoterodine plus fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 1, 2011 · Synced Oct 6, 2026, 4:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or Pharmacotherapy

NCT01829425
View directory record Official record
Conditions
Urinary Incontinence, Urge
Interventions
Anticholinergic medications, Hypnotherapy
Drug · Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 6, 2026, 4:03 PM EDT
Completed No phase listed Observational

Intermittent Hypoxemia and Acute Kidney Injury Study (IHAKI Study)

NCT02837276
View directory record Official record
Conditions
Intermittent Hypoxemia, Acute Kidney Injury, Preterm Infant
Interventions
Not listed
Lead sponsor
Elie G. Abu Jawdeh, MD
Other
Eligibility
Up to 2 Months
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 6, 2026, 4:03 PM EDT